Publications 2025 – 2026

Publications 2026

Abdoul J, Luc N, Joly BS, Jehl A, Blandinières A, Adam F, Duhaut L, Aljhni R, Grimaldi L, Lenting PJ, Sen Gupta A, Denis CV, Roullet S. Total thrombus formation system exploration of primary hemostasis in cirrhotic patients. Res Pract Thromb Haemost. 2026, 10, 103370. doi: 10.1016/j.rpth.2026.103370.

Astermark J, Hermans C, Lenting PJ, O’Donnell JS, on behalf of the Factor Think Tank. Nine areas with outstanding challenges for hemophilia B research. Ther Adv Hematol. 2026, 17, 20406207251409300. doi: 10.1177/20406207251409300.

Atsou S, Rinsant A, Casari C, Lenting PJ, Javaugue V, Desport E, Macchi L, Denis CV, Bridoux F, Christophe OD. Factor X colocalizes with amyloid light chain deposits in AL amyloidosis: evidence from three patients. Haematologica. 2026. doi: 10.3324/haematol.2026.300598.

Auditeau C, Bianchini EP, Peyron I, Ruty A, Saenjamsai P, Khamari M, Hackeng TM, Christophe OD, Denis CV, Borgel D, Lenting PJ, Saller F. Anti-TFPI single-domain antibodies: novel rebalancing therapies for hemophilia and other rare bleeding disorders. Thromb Haemost. 2026. doi: 10.1055/a-2894-0856.

Auditeau C, Valsecchi C, Bentounes NK, Le-Goff A, Harroche A, Bally C, Lenting PJ, Borgel D, Peyvandi F, Lasne D. Implementing an assay detecting anti-drug antibody against emicizumab: experience from one center in France. Thromb Haemost. 2026, 126, 359–370. doi: 10.1055/a-2632-3001.

Bär I, Groten SA, Barraclough A, Bürgisser PE, van Kwawegen C, Lenting PJ, van Moort I, Eikenboom JCJ, Leebeek FWG, Voorberg J, van den Biggelaar M, Bierings R. Allele-selective disruption of pathogenic VWF variants in type 2 von Willebrand disease using CRISPR/Cas9. Blood Adv. 2026, 10, 1429–1443. doi: 10.1182/bloodadvances.2025018760.

Casari C, Leebeek FWG, Peyvandi F. Historical, current and future treatments for von Willebrand disease. Haematologica. 2026, 111, 54–66. doi: 10.3324/haematol.2024.286037.

Casari C, Sadler B, Susen S, Lassila R. Von Willebrand disease: a century of progress. Res Pract Thromb Haemost. 2026, 10, 106790. doi: 10.1016/j.rpth.2026.106790.

Denis CV, Casari C, Christophe OD, Lenting PJ. Murine models of hemostasis: how to assess bleeding in mice and clinical relevance of these models for testing new therapeutics. Arterioscler Thromb Vasc Biol. 2026, 46, e323863. doi: 10.1161/ATVBAHA.126.323863.

Galeotti C, Rauch A, Gatti H, Desage S, Butelet A, Biron-Andreani C, Susen S, d’Oiron R, Chanteau G, Proulle V, Dargaud Y. Real-world effectiveness and safety of concizumab prophylaxis in hemophilia: results from a national French cohort. Haemophilia. 2026. doi: 10.1111/hae.70290.

McCluskey G, Maynadié H, Borgel D, Frenzel L, Harroche A, Bianchini EP, Roullet S, Christophe OD, Denis CV, Casari C, Lenting PJ. Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms. HemaSphere. 2026, 10, e70376. doi: 10.1002/hem3.70376.

Védrenne A, Habarou F, Pascreau T, Vasse M. Comparison of complete blood count results between K3-EDTA- and MgSO4-anticoagulated samples using a DxH800 analyzer. J Clin Med. 2026, 15, 4607. doi: 10.3390/jcm15124607.

Zolala M, Heim V, Denis CV, Lenting PJ, Mangin PH, Hermans TM. Magnetostaltic pumping in an ex vivo extracorporeal membrane oxygenation model. J Transl Med. 2026, 24, 252. doi: 10.1186/s12967-026-07734-w.

Publications 2025
  • Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell NT, Crato M, Dargaud Y, d’Oiron R, Dunn AL, Escobar MA, Ettingshausen CE, Fischer K, Gouider E, Harroche A, Hermans C, Jimenez-Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Mancuso ME, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O’Mahony B, Ozelo M, Pierce GF, Ramos G, Recht M, Romero-Lux O, Rotellini D, Santoro RC, Singleton TC, Skinner MW, Srivastava A, Susen S, Talks K, Tran H, Valentino LA, Windyga J, Yang R; also on behalf of AICE, AHAD‐AP, AHCDC, ATHN, CLAHT, EHC, French CRH & MHEMO, GTH, HTCCNC, NBDF, PEDNET, UKHCDO, WFH. International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal. Haemophilia. 2024 Dec 6.doi: 10.1111/hae.15135
  • Auditeau C, Nguyen TS, Devaux F, Saller F, Peyron I, Blandinieres A, Reperant C, Darame S, Denis C, Lenting PJ, Borgel D, Bianchini EP. An inhibitory single-domain antibody against protein Z-dependent protease inhibitor promotes thrombin generation in hemophilia A and FXI deficiency. Thromb Haemost. 2025 Mar;125(3):207-217. doi: 10.1055/a-2373-2829.
  • Bogey C, Rouchaud A, Gentric JC, Beaufreton E, Timsit S, Clarencon F, Caroff J, Bourcier R, Zhu F, Dargazanli C, Hak JF, Boulouis G, Ifergan H, Pop R, Forestier G, Lapergue B, Ognard J; Etis Investigators. Predictive models of clinical outcome of endovascular treatment for anterior circulation stroke using machine learning. J Neurosci Methods. 2025 Apr;416:110376. doi: 10.1016/j.jneumeth.2025.110376.
  • Burel J, Agripnidis T, Rouchaud A, Marnat G, Caroff J, Zhu F, Kerleroux B, Berge J, Pruvo JP, Desal H, Boulouis G; SFNR Board. Interventional neuroradiology in France in 2025: Scaling up expertise, access, and innovation. J Neuroradiol. 2025 May 14;52(4):101350.
  • Deliktas Y, Derraz I, Finitsis S, Caroff J, Bourcier R, Soize S, Moulin S, Richard S, Marnat G, Hoferica M, Cognard C, Desilles JP, Anadani M, Olivot JM, Casolla B, Consoli A, Lapergue B, Gory B; ETIS Registry Investigators. Clinical and safety outcomes of acute stenting plus thrombectomy for carotid tandem lesions with large ischemic core. J Neurointerv Surg. 2025 Jan 26:jnis-2024-022155.
     doi: 10.1136/jnis-2024-022155.
  • Devauchelle P, Bignon A, Breteau I, Defaye M, Degravi L, Despres C, Godon A, Guérin R, Lavayssiere L, Lebas B, Maurice A, Monet C, Monsel A, Reydellet L, Roullet S, Rozier R, Guichon C, Weiss E; for the French Special Interest Group “Liver Anesthesiology and Intensive Care”. Perioperative Management During Liver Transplantation: A National Survey From the French Special Interest Group in « Liver Anesthesiology and Intensive Care ». Transplantation 2025 Apr 1;109(4):671-680. doi: 10.1097/TP.0000000000005264
  • Dubois MD, Pierre-Louis ON, Pierre-Louis S, Boisseau P, Denis CV, Dupont A, Goudemand J, Casari C, Jeanpierre E, Zawadzki C, Ferrey B, Rabout J, Fuseau P, Chonville E, Michel F, Yerro MN, Gruel Y, Christophe O, Lenting PJ, Janky E, Susen S, Neviere R. Clinical, Phenotypic and Genotypic Characteristics of Von Willebrand Disease in Afro-Caribbeans: Results From a Study in Martinique Island, French West Indies. Haemophilia 2025 May;31(3):458-476. doi: 10.1111/hae.70003.
  • El Hamaoui D, Marchelli A, Gandrille S, Reboul E, Stepanian A, Palmier B, Jovine L, Lebrin F, Smadja DM, Bernabeu C, Denis CV, Gaussem P, Pasquali S, Kauskot A, Rossi E. Thrombin cleaves membrane-bound endoglin potentially contributing to the heterogeneity of circulating endoglin in preeclampsia. Commun Biol. 2025 Feb 26;8(1):316. doi: 10.1038/s42003-025-07751-3.
  • Ifergan H, Dargazanli C, Hassen WB, Hak JF, Gory B, Ognard J, Premat K, Marnat G, Kerleroux B, Zhu F, Bellanger G, Sporns PB, Charbonnier G, Forestier G, Caroff J, Fauché C, Clarençon F, Janot K, Lapergue B, Boulouis G; ETIS registry collaborators and the JENI research collaborative. Determinants of day-1 stent patency following rescue intracranial stenting in failed intracranial thrombectomy. Interv Neuroradiol. 2025 May 21:15910199251339900. doi: 10.1177/15910199251339900.
  • Kartal-Kaess M, Pinto F, Labarque V, de Kovel M, Nolan B, Carcao M, d’Oiron R, Stamm Mikkelsen T, Ljung R, Andersson NG; PedNet Study Group. Hemophilia B Leyden: Characteristics and natural history in the PedgNet Registry. J Thromb Haemost. 2025 Mar;23(3):921-927.
  • Kauskot A, Ramstrom S, Nipoti T, van der Wal DE. Consensus protocol for platelet desialylation (β-galactose exposure) quantification using lectins by flow cytometry: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2025 Jun;23(6):2050-2059.
  • Linthorst NA, Jongejan YK, Dirven RJ, Laan SNJ, Bierings R, Casari C, Cordfunke RA, Dahlman JE, Dolezal N, Drijfhout JW, Leebeek FWG, Ruhaak LR, Echeverri LS, Voorberg J, van Vlijmen BJM, Denis CV, Eikenboom JCJ. Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs. Blood Adv. 2025 2025 Jan 28;9(2):310-320. doi: 10.1182/bloodadvances.2024014601.
  • Lordier L, Di Buduo CA, Kauskot A, Balayn N, Lavenu-Bombled C, Baschieri F, Proulle V, Oyarzun CPM, Careddu F, Biunno I, Manoliu T, Rameau P, Plo I, Papadopoulos N, Constantinescu S, Vainchenker W, Nguyen GN, Ballerini P, Favier R, Balduini A, Raslova H. Increased RhoA pathway activation downstream of αIIbβ3/SRC contributes to heterozygous Bernard Soulier syndrome. Haematologica. 2025 Jul 1;110(7):1596-1609. doi: 10.3324/haematol.2024.286424.
  • McCluskey G*, Heestermans M*, Peyron I, Pascal E, Clavel M, Bun E, Bocquet E, Reperant C, Susen S, Christophe O, Denis CV, Lenting PJ*, Casari C*. A fully humanized von Willebrand disease-type 1 mouse model as unique platform to investigate novel therapeutic options. Haematologica, 2025 Apr 1;110(4):923-937. * Co-first and co-last authors.
  • Milnerowicz M, Desilles JP, Pop R, Dargazanli C, Labreuche J, Sibon I, Gory B, Soize S, Bourcier R, Mazighi M, Cognard C, Caroff J, Gentric JC, Clarençon F, Richter S, Janot K, Lapergue B, Marnat G; ETIS investigators. Cangrelor versus GPIIb/IIIa inhibitors as adjunctive therapy in endovascular treatment of large vessel occlusion stroke. J Neurointerv Surg. 2025 May 2:jnis-2025-023260. doi: 10.1136/jnis-2025-023260.
  • Perrier-Cornet A, Gendron N, Desconclois C, Planche V, Vayne C, Gac FN, Lavenu-Bombled C, Lasne D, Flaujac C, Hormi M. [Overview of practices among French clinical pathologists specialized in haemostasis]. Ann Biol Clin (Paris). 2025 May 22;83(2):147-60.
  • Pop R, Finitsis SN, Marnat G, Derraz I, Cognard C, Calviere L, Caroff J, Clarençon F, Delvoye F, Consoli A, Lapergue B, Gory B; ETIS Registry Investigators. Cangrelor for emergent carotid stenting during stroke thrombectomy: a comparative analysis versus glycoprotein IIb/IIIa inhibitors or aspirin monotherapy. J Neurointerv Surg. 2025 Jun 1;17(e2):e269-e275.
  • Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M, Petit A, Boutroux H, Desprez D, Fiore M, d’Oiron R, Alessi MC. Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. Haemophilia. 2025 Jan;31(1):7-15. doi: 10.1111/hae.15130.
  • Sefiane T, McCluskey G, Clavel M, Maynadié H, Peyron I, Tovo D, Brochier C, Saller F, Khamari M, Denis CV, Christophe OD, Lenting PJ, Muxczynski V*, Casari C*. A consistent clinical factor VIII-equivalence is unlikely to exist for non-factor therapies in hemophilic mice. Haematologica. 2025 Apr 3. doi: 10.3324/haematol.2024.286982.
  • Skinner MW, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell NT, Crato M, Dargaud Y, d’Oiron R, Dunn AL, Escobar MA, Escuriola-Ettingshausen C, Gouider E, Harroche A, Hermans C, Jimenez-Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O’Mahony B, Ozelo M, Pierce GF, Ramos G, Recht M, Romero-Lux O, Rotellini D, Santoro RC, Singleton TC, Srivastava A, Susen S, Talks K, Tran H, Valentino LA, Windyga J, Yang R, Mancuso ME; also on behalf of AICEAHAD‐APAHCDCATHNCLAHTEHCFrench CRH & MHEMOHTCCNCNBDFPEDNETUKHCDOWFH. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease. Haemophilia 2024 Dec 9. doi: 10.1111/hae.15136.
  • Spelle L, Costalat V, Caroff J, Wodarg F, Fischer S, Herbreteau D, Möhlenbruch MA, Januel AC, Papagiannaki C, Klisch J, Numminen J, Rautio R, Berlis A, Mihalea C, Chalumeau V, Downer J, Cortese J, Ikka L, Gallas S, Bester M, Liebig T, Velasco S, Grimaldi L, Byrne J, Szikora I, Pierot L, Cognard C. CLinical EValuation of WEB 17 device in intracranial aneuRysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms. J Neurointerv Surg. 2025 Jul 14;17(8):878-882.
  • Tournier L, Cortese J, Consoli A, Spelle L, Marnat G, Sarov M, Zhu F, Soize S, Burel J, Forestier G, Escalard S, Pop R, Bonnet B, Alias Q, Ognard J, Naggara O, Kyheng M, Lapergue B, Caroff J; ETIS Registry Investigators. Mechanical thrombectomy in basilar artery occlusions: impact of first-line strategy as a function of the occlusion level. J Neurointerv Surg. 2025 Mar 17;17(4):346-353.
  • Volot F, Castet S, Fournel A, Frotscher B, Gillet B, Desprez D, Tardy B, Rauch A, Chamouni P, Biron-Andreani C, Valentin JB, Harroche A, Dargaud Y, Petesch BP, d’Oiron R, Berger C, Reynes C, Lauvray T, de Raucourt E, Hassoun A, Lebreton A, Cussac V, Catovic H, Martin C, Guillet B. ORPHEE: A Real-World Study on rIX-FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B. Eur J Haematol. 2025 Mar;114(3):508-516.
  • Wheeler AP, Abraham A, Barnes C, Brown Frandsen R, d’Oiron R, Eichler H, Hampton K, López-Jaime FJ, Lyu CJ, Tavares CMM, Nogami K, Sutton C, Windyga J, Zulfikar B, Castaman G. Real-World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End-of-Study Results From the explorer6 Non-Interventional Study. Haemophilia 2025 May 5. doi: 10.1111/hae.70051.

Défiler vers le haut